INTRODUCTION
It has been 13 years since the Biologics Price Competition and
Innovation Act (BPCIA) was enacted and biosimilars had a pathway to
enter the U.S. market. While there have been challenges over this
time, the U.S. biosimilar market has come a long way and has
overcome many hurdles. We will explore some of the issues
biosimilars have faced when entering the U.S. market, with a
particular focus on the impact of inter partes reviews (IPRs), post
grant reviews (PGRs), and the BPCIA litigation patent dance, as
well as challenges to gaining market share after launch.
THE CURRENT STATE OF THE BIOSIMILARS INDUSTRY IN THE U.S.
There are currently1 40 approved biosimilars of 11
reference products in the U.S. market, seven of which were approved
in 2022. This is a marked increase over the prior two years, which
had seven total approvals due to COVID-19 related approval delays.
Thus far, interchangeable approvals have been limited, with only
four approved